PDCD1 and neoplasm: Moreover, in the isogenic and immunocompetent B16-F10 mouse melanoma model, oral–twice daily dosing of 0.1–10 mg/kg OM-153 potentiated efficacy of anti–PD-1 treatment and resulted in a 51%–65% tumor growth inhibition.